Johnson & Johnson (NYSE:JNJ) announced on Saturday the initial results from a group of patients who were part of its ...

Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in ...